Papers by Hagop M. Kantarjian
Page 9 · newest first
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid LeukemiasActa Haematologica · 2020
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaBlood · 2019
- Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical managementCancer · 2019
- Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaCancer · 2019
- Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaBlood · 2019
- Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing AnalysesBlood · 2019
- A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic LeukemiaBlood · 2019
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaBlood · 2019
- Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)Blood · 2019
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyBlood · 2019
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of CyclesBlood · 2019
- Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)Blood · 2019
- The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survivalAmerican Journal of Hematology · 2019
- Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemiaBlood Advances · 2019
- Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemiaCancer · 2019
- Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationAmerican Journal of Hematology · 2019
- Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsAmerican Journal of Hematology · 2019
- Targeted therapy paves the way for the cure of acute lymphoblastic leukaemiaBritish Journal of Haematology · 2019
- Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disordersHaematologica · 2019
- Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemiaCancer · 2019
- CPX-351 (vyxeos) in AMLLeukemia & lymphoma/Leukemia and lymphoma · 2019
- Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United StatesCancer Medicine · 2019
- Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatmentCancer Medicine · 2019
- Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 studyCancer · 2019
- Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International CohortsJournal of Clinical Oncology · 2019
- Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutationAmerican Journal of Hematology · 2019
- Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaClinical Epigenetics · 2019
- Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemiaAmerican Journal of Hematology · 2019
- Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibAmerican Journal of Hematology · 2019
- Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaCancer · 2019
- Ibrutinib and Venetoclax for First-Line Treatment of CLLNew England Journal of Medicine · 2019
- Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyLeukemia & lymphoma/Leukemia and lymphoma · 2019
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsHaematologica · 2019
- Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD 33 expression and in vitro response to targeted CD 33 therapyBritish Journal of Haematology · 2019
- Recent advances in the treatment of acute lymphoblastic leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2019
- Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaBiology of Blood and Marrow Transplantation · 2019
- Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell TransplantationBiology of Blood and Marrow Transplantation · 2019
- Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysisCancer · 2019
- DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk diseaseAmerican Journal of Hematology · 2019
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaLeukemia · 2019
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyCancer · 2019
- NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyBlood Advances · 2019
- Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIsBlood Advances · 2019
- Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndromeCancer · 2019
- NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemiaAmerican Journal of Hematology · 2019
- Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemiaCancer · 2019
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetBlood · 2019
- Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapyBlood · 2019
- BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironmentJournal of Clinical Investigation · 2019
- Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapyOncotarget · 2019